BALTIMORE, MD--(Marketwired - Aug 6, 2013) - In a newly released research update, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a research update that Nuvilex Inc.'s (
Nuvilex owns exclusive worldwide rights to the live-cell encapsulation-based platform technology for any and all cancer types, including a pancreatic cancer treatment that successfully completed Phase II clinical trials. This platform, which essentially serves as an existing therapy booster, is based upon its live-cell encapsulation technology and delivery system and enhances the quality of life.
In the Goldman Opportunity Research update on the Company, analyst Rob Goldman outlines his investment thesis.
"On the heels of the recent cancer treatment transaction, management noted that Nuvilex intends to acquire the worldwide exclusive rights to the use of the live-cell encapsulation technology for the development of treatments for diabetes from SG Austria with the closing of the transaction expected at the end of October 2013. Estimated annual diabetes drug sales in the U.S. are $22 billion, thus providing huge market potential for the Company. Funds for this acquisition have already been committed and the final paperwork is executed."
"Given the correlation between individuals with diabetes and their 8-fold increased risk for pancreatic cancer, it is a natural fit into at least one of the Company's overall clinical directions. Management plans to begin preparing for future in-depth studies in the fourth quarter of this year. Considering that the diabetes treatment data indicates that it could eliminate the need for insulin therapy, Nuvilex is moving toward introducing a game-changing treatment platform that is potentially worth billions in annual sales. Moreover, Nuvilex has now transformed itself into a major player in two of the largest and most lucrative health care treatment categories, oncology and diabetes."
To view Nuvilex reports and articles or to download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (
- Health Care Industry
- pancreatic cancer